UNIQURE N.V. news, videos and press releases
For more news please use our advanced search feature.
UNIQURE N.V. - More news...
UNIQURE N.V. - More news...
- uniQure Announces 2024 Financial Results and Highlights Recent Company Progress
- uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
- uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS
- uniQure Announces Pricing of its Public Offering
- uniQure Announces Proposed Public Offering
- uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease
- uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy
- uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress
- uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS
- uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease
- uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
- uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update
- uniQure Announces Closing of Sale of Manufacturing Facility to Genezen
- uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease
- uniQure Announces Sale of Commercial Manufacturing Facility to Genezen
- uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease
- uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
- uniQure Announces 2023 Financial Results and Highlights Recent Company Progress
- uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
- uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease
- uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
- uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting
- uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs
- uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy
- uniQure Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
- uniQure Announces Leadership Addition to Support Advancement of Clinical Programs
- INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against uniQure N.V. and Encourages Investors with Losses to Contact the Firm
- INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against uniQure N.V. and Encourages Investors with Losses to Contact the Firm
